Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 4, 2014, Pages 561-571

  Wang, Hsei Wei ^b,c   Yang, Shung Haur ^a,b   Huang, Guan Da ^a   Lin, Jen Kou ^a,b   Chen, Wei Shone ^a,b   Jiang, Jeng Kai ^a,b   Lan, Yuan Tzu ^a,b   Lin, Chun Chi ^a,b   Hwang, Wei Lun ^b,c   Tzeng, Cheng Hwai ^a,b   Li, Anna Fen Yau ^a,b   Yen, Chueh Chuan ^a,b   Teng, Hao Wei ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

AKT; Autophagy; Erk; mTOR

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CETUXIMAB; CHLOROQUINE; EPIDERMAL GROWTH FACTOR; K RAS PROTEIN; LEUPEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHORYLATED EXTRACELLULAR REGULATED PROTEIN KINASE; PHOSPHORYLATED V AKT MURINE THYMOMA VIRAL ONCOGENE; PROTEIN KINASE B; SMALL INTERFERING RNA; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CANCER PROGNOSIS; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH VESSEL METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOANTIGENS; BLOTTING, WESTERN; CELL PROLIFERATION; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIROLIMUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899487573     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1596-4     Document Type: Article

References (33)

1. Bockelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Butzow R, Ristimaki A (2011) Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 105(7):989-995. doi:10.1038/bjc.2011.346
2. Bockelman C, Koskensalo S, Hagstrom J, Lundin M, Ristimaki A, Haglund C (2012) CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther 13(5):289-295. doi:10.4161/cbt.18922
3. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Kohne CH (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48(10):1466-1475. doi:10.1016/j.ejca.2012.02.057
4. Chen W, Arroyo JD, Timmons JC, Possemato R, Hahn WC (2005) Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res 65(18):8183-8192. doi:10.1158/0008-5472.CAN-05-1103 (Pubitemid 41330582)
5. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL (2010a) CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene. doi:10.1038/onc.2010.357
6. Chen XG, Liu F, Song XF, Wang ZH, Dong ZQ, Hu ZQ, Lan RZ, Guan W, Zhou TG, Xu XM, Lei H, Ye ZQ, Peng EJ, Du LH, Zhuang QY (2010b) Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways. Mol Carcinog 49(6):603-610. doi:10.1002/mc.20628
7. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
8. Coenen EA, Zwaan CM, Meyer C, Marschalek R, Pieters R, van der Veken LT, Beverloo HB, van den Heuvel-Eibrink MM (2010) KIA1524: a novel ML translocation partner in acute myeloid leukemia. Leuk Res. doi:10.1016/j.leukres.2010.08.017
9. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thezenas S, Westermarck J (2009) CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 15(16):5092-5100. doi:10.1158/1078-0432.CCR-08-3283
10. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, Wang EH (2010) CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. doi:10.1245/s10434-010-1313-8
11. Fang JY, Richardson BC (2005) The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6(5):322-327. doi:10.1016/S1470-2045(05)70168-6 (Pubitemid 40590269)
12. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B (2009) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(23):3822-3829. doi:10.1200/JCO.2008.20. 7977
13. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271-2281. doi:10.1056/NEJMoa066838 (Pubitemid 46849157)
14. Hui L, Rodrik V, Pielak RM, Knirr S, Zheng Y, Foster DA (2005) mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. J Biol Chem 280(43):35829-35835. doi:10.1074/jbc.M504192200 (Pubitemid 41633850)
15. Junttila MR, Westermarck J (2008) Mechanisms of MYC stabilization in human malignancies. Cell Cycle 7(5):592-596 (Pubitemid 351498996)
16. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grenman R, Kast J, Kallunki T, Sears R, Kahari VM, Westermarck J (2007) CIP2A inhibits PP2A in human malignancies. Cell 130(1):51-62. doi:10.1016/j.cell.2007.04.044 (Pubitemid 47039258)
17. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimaki A (2009) MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 101(11):793-805. doi:10.1093/jnci/djp103
18. Kroemer G, Marino G, Levine B (2010) Autophagy and the integrated stress response. Mol Cell 40(2):280-293. doi:10.1016/j.molcel.2010.09.023
19. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274-293. doi:10.1016/j.cell.2012.03.017
20. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, Xu D (2008) CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 14(12):3722-3728. doi:10.1158/1078-0432.CCR-07-4137
21. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249-279. doi:10.1016/j.advenzreg.2006.01.004 (Pubitemid 44301348)
22. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A (2012) Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 18(9):2515-2525. doi:10.1158/1078-0432.CCR-11-2683
23. Peterson RT, Desai BN, Hardwick JS, Schreiber SL (1999) Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci USA 96(8):4438-4442 (Pubitemid 29190354)
24. Populo H, Lopes JM, Soares P (2012) The mTOR signalling pathway in human cancer. Int J Mol Sci 13(2):1886-1918. doi:10.3390/ijms13021886
25. Qin L, Wang Z, Tao L, Wang Y (2010) ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. Autophagy 6(2):239-247
26. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013-2019. doi:10.1200/JCO.2007.14.9930
27. Teng HW, Huang YC, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Wang HW, Chang SC, Lan YT, Lin CC, Wang HS, Yang SH (2012a) BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol 106(2):123-129. doi:10.1002/jso.23063
28. Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Chen PC, Lan YT, Lin CC, Hsu YN, Wang HW, Chen KF (2012b) CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest surg 16(5):1037-1047. doi:10.1007/s11605-012-1828-3
29. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF (2012) CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res BCR 14(2):R68. doi:10.1186/bcr3175
30. Vaarala MH, Vaisanen MR, Ristimaki A (2010) CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 29(1):136. doi:10.1186/1756-9966-29- 136
31. Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mader U, Gasser M, Waaga-Gasser AM, Eilers M, Germer CT (2013) CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS ONE 8(10):e75292. doi:10.1371/journal.pone.0075292
32. Windsor AC, Cohen R, Jiao LR, Stebbing J (2008) Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear. Future Oncol 4(6):741-744. doi:10.2217/14796694.4.6.741
33. Zhao D, Liu Z, Ding J, Li W, Sun Y, Yu H, Zhou Y, Zeng J, Chen C, Jia J (2010) Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways. J Med Microbiol 59(Pt 3):259-265. doi:10.1099/jmm.0. 014704-0